• 1
    Adam R, McMaster P, O'Grady JG et al. Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 12311243.
  • 2
    Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666678.
  • 3
    Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1S9.
  • 4
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28S34.
  • 5
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 6
    Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619625.
  • 7
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 8
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 9
    Bizollon T, Ahmed SN, Radenne S et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 10
    Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642650.
  • 11
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 12
    Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 11601161.
  • 13
    Gadano AC, Mosnier JF, Durand F et al. alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59: 16271629.
  • 14
    Saab S, Kalmaz D, Gajjar NA et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859867.
  • 15
    Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850858.
  • 16
    Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22(4 Pt 1): 10841089.
  • 17
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 18
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166173.
  • 19
    Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190194.
  • 20
    Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 12531258.
  • 21
    Berenguer M, Prieto M, Palau A et al. Recurrent hepatitis C genotype 1b following liver transplantation: Treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 12071212.
  • 22
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 23
    Lavezzo B, Franchello A, Smedile A et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247252.
  • 24
    Gopal DV, Rabkin JM, Berk BS et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181190.
  • 25
    Jain A, Demetris AJ, Manez R et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998; 4: 197203.
  • 26
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863869.
  • 27
    Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 28
    Alberti AB, Belli LS, Airoldi A et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001; 7: 870876.
  • 29
    De Vera ME, Smallwood GA, Rosado K et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678686.
  • 30
    Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20(1 Pt 1): 1520.
  • 31
    Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658663.
  • 32
    Demetris A, Adams D, Bellamy C et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792799.
  • 33
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512516.
  • 34
    Magnone M, Holley JL, Shapiro R et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 10681070.
  • 35
    Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: An analysis of the UNOS data. Am J Transplant 2006; 6: 13981406.
  • 36
    Bizollon T, Pradat P, Mabrut JY et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 19091913.
  • 37
    Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10: 868871.
  • 38
    Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 34873493.
  • 39
    Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 40
    Berenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998; 28: 756763.
  • 41
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477481.
  • 42
    Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38: 14801484.
  • 43
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495500.